Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (6390)	5/30/1998 1:44:00 AM
From: aknahow	Respond to of 17367

Opala, I did answer but ended up not posting it thinking it was not really necessary. I believe things like the oncotic pressure of the patients make it possible for some to know who received a placebo and who did not. Dr. Saul Faust at St. Mary's as quoted in the London Times said the protein derived from white blood cells worked. Was he referring to the present trials or to the P II trial? Not 100% clear. I e mailed him and he asked if I was a doctor. When I said he wasn't there was no further communication. I do not see the price action the same way you do. Over the the last few years there have been higher highs and higher lows. Taipan recently pointed to this. Tharos has pointed out that while this is correct over the long term the shorter term technicals have not been as strong and that if the stock does not continue to move up the long term picture will cease to be as attractive. Taipan also points to institutional accumulation. I think there is some concerted effort to induce individual shareholders confidence to reduce the cost of accumulation. Remember at Yahoo names can be changed at will. Did research_hound find another hydrant or has he become a mentor. Does a funny guy make any sense or is he BUNDAMANs neighbor? The science means a lot to me . I remain impressed with XOMAs patents, and also managements decisions. Look at CBMI with a great partnership and all of a sudden issuing convertible pfd, (with sufficient restrictions). Trials take time, but when and if the meningococcemia trial is completed successfully remember there is no partner to take the lions share and agreements can be negotiated from strength.

To: opalapril who wrote (6390)	5/30/1998 11:40:00 AM
From: Tharos	Read Replies (1) \| Respond to of 17367

It's in the darkest hours that you make your biggest mistakes. Don't listen to the "Engine that can't" at Yahoo! or the other boards where people complain about poor management if they don't get a triple on their money within two days of investing it. Historically, Xoma deserves to be ignored and that's what makes it such a great play. Unfortunately, as with all fundamental investing, you can end up waiting a long time for the rest of the market to become "as smart as you have been all along." Compound this with other stocks making huge gains in the same time span. Can wear one down. Having been upfront all along about Xoma being a small part of my total holdings, I happily admit to having enjoyed "no-brainer" gains in the recent market. Hope this cheers you up a bit: Prohost April-May 1998 Biotechnology Momentum Prohost Club Biotechs With No Approved Products XOMA: (XOMA-Nasdaq) Xoma is cruising towards becoming what it would have been years ago if not for the unfortunate tragedy in 1992 when its very well developed product faced a rejection caused by many factors unrelated to the product's safety or efficacy. The firm's products derived from BPI are extremely promising for curing bacterial and fungal infections and sepsis. Our excitement about Neuprex, however, stems from the fact that this product is not intended to be an antibiotic but rather an adjuvant that will boost antibiotics to conquer those nasty resistant microbial strains mid reverse the symptoms of life threatening sepsis. Why this enthusiasm? Because if proven successful, the product will be used with all antibiotics in most, if not all, cases where infection begins to express the slightest signs of resistance to any antibiotics. Moreover, the product is turning out to be important in emergency medicine. In this domain, physicians do not ask the resistant insurance companies what they should or should not administer to patients in order to save their lives. Rather, they listen to the stubborn microbes to figure out a way to destroy them. Xoma. is doing a good job also in proving its technology and licensing it to companies, generating quick bucks. Its product anti-CD11a, developed jointly with Genentech, has shown encouraging preliminary results. If proven successful, this product could become a best seller. Psoriasis is a hot target and the number of patients is large. Copyright Prohost Reserch Group, Prohost@aol.com